B cell depletion changes the immune cell profile in multiple sclerosis patients: One-year report

Achiron, 2020, Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies, Ther. Adv. Neurol. Disord., 14 Allegretta, 1990, T cell responsive to myelin basic protein in patients with multiple sclerosis, Science, 247, 718, 10.1126/science.1689076 Aqel, 2019, Novel small molecule IL-6 inhibitor suppresses autoreactive Th17 development and promotes Treg development, Clin. Exp. Immunol., 196, 215, 10.1111/cei.13258 Aqel, 2021, Selective inhibition of STAT3 with a novel small molecule improves Teff:Treg balance and ameliorates CNS autoimmunity, JCI Insight, 142376 Badami, 2019, Activation-induced cell death of self-reactive regulatory T cells drives autoimmunity, Proc. Natl. Acad. Sci. U. S. A., 116, 26788, 10.1073/pnas.1910281116 Baecher-Allan, 2018, Multiple sclerosis: mechanisms and immunotherapy, Neuron, 97, 742, 10.1016/j.neuron.2018.01.021 Bar-Or, 2008, Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial, Ann. Neurol., 63, 395, 10.1002/ana.21363 Bigaut, 2021, Impact of disease-modifying treatments on humoral response after COVID-19 vaccination: a mirror of the response after SARS-CoV-2 infection, Rev. Neurol. (Paris), 10.1016/j.neurol.2021.05.001 Burnard, 2017, EBV and MS: major cause, minor contributor or red-herring?, Mult. Scler. Relat. Disord., 16, 24, 10.1016/j.msard.2017.06.002 Burns, 1999, Isolation of myelin basic protein-specific T cells predominantly from the memory T-cell compartment in multiple sclerosis, Ann. Neurol., 45, 33, 10.1002/1531-8249(199901)45:1<33::AID-ART7>3.0.CO;2-G Chen, 2019, CXCR5+PD-1+ follicular helper CD8 T cells control B cell tolerance, Nat. Commun., 10, 4415, 10.1038/s41467-019-12446-5 Chen, 2020, Apremilast regulates the Teff/Treg balance to ameliorate uveitis via PI3K/AKT/FoxO1 signaling pathway, Front. Immunol., 11, 581673, 10.3389/fimmu.2020.581673 Codarri, 2011, RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation, Nat Immunol, 12, 560, 10.1038/ni.2027 Cross, 2006, Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients, J. Neuroimmunol., 180, 63, 10.1016/j.jneuroim.2006.06.029 Deola, 2017, Evidence for CD19B-CD8T cell interactions in blood and tissues from patients with GvHD, Bone Marrow Transplant., 52, 459, 10.1038/bmt.2016.294 Desai, 2020, Lack of B lymphocytes enhances CD8 T cell-mediated resistance against respiratory viral infection but compromises memory cell formation, J. Virol., 94, 10.1128/JVI.01877-19 El-Behi, 2011, The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF, Nat Immunol, 12, 568, 10.1038/ni.2031 Fox, 2021, A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis, Mult. Scler., 27, 420, 10.1177/1352458520918375 Gingele, 2018, Ocrelizumab depletes CD20+ T cells in multiple sclerosis patients, Cells, 8, 12, 10.3390/cells8010012 Guerieri, 2021, Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience, J. Neurol., 1 Haas, 2007, Prevalence of newly generated naive regulatory T cells (Treg) is critical for Treg suppressive function and determines Treg dysfunction in multiple sclerosis, J. Immunol., 179, 1322, 10.4049/jimmunol.179.2.1322 Haas, 2005, Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis, Eur. J. Immunol., 35, 3343, 10.1002/eji.200526065 Hauser, 2008, B-cell depletion with rituximab in relapsing-remitting multiple sclerosis, New Engl. J. Med., 358, 676, 10.1056/NEJMoa0706383 Hauser, 2017, Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis, New Engl. J. Med., 376, 221, 10.1056/NEJMoa1601277 Hawker, 2009, Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial, Ann. Neurol., 66, 460, 10.1002/ana.21867 Hermann, 1995, CD40 ligand-positive CD8+ T cell clones allow B cell growth and differentiation, Eur. J. Immunol., 25, 2972, 10.1002/eji.1830251039 Hladfkova, 2019, Tumor-infiltrating B cells affect the progression of oropharyngeal squamous cell carcinoma via cell-to-cell interactions with CD8+ T cells, J. Immunother. Cancer, 7, 261, 10.1186/s40425-019-0726-6 Holley, 2014, CD20+ inflammatory T-cells are present in blood and brain of multiple sclerosis patients and can be selectively targeted for apoptotic elimination, Mult. Scler. Relat. Disord., 3, 650, 10.1016/j.msard.2014.06.001 Huan, 2005, Decreased FOXP3 levels in multiple sclerosis patients, J. Neurosci. Res., 81, 45, 10.1002/jnr.20522 Jelcic, 2018, Memory B cells activate brain-homing, autoreactive CD4+ T cells in multiple sclerosis, Cell, 175, 85, 10.1016/j.cell.2018.08.011 Kantengwa, 2007, Inhibition of naïve Th1 CD4+ T cells by glatiramer acetate in multiple sclerosis, J. Neuroimmunol., 185, 123, 10.1016/j.jneuroim.2006.12.014 Kappos, 2011, Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial, Lancet, 378, 1779, 10.1016/S0140-6736(11)61649-8 Kitz, 2018, Regulatory T cells: from discovery to autoimmunity, Cold Spring Harb. Perspect. Med., 8, 10.1101/cshperspect.a029041 Kumar, 2006, CD4+CD25+FoxP3+ T lymphocytes fail to suppress myelin basic protein-induced proliferation in patients with multiple sclerosis, J. Neuroimmunol., 180, 178, 10.1016/j.jneuroim.2006.08.003 Laurence, 2017, Epstein-Barr virus and multiple sclerosis: updating Pender’s hypothesis, Mult. Scler. Relat. Disord., 16, 8, 10.1016/j.msard.2017.05.009 Le Garff-Tavernier, 2014, Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion, Leukemia, 28, 230, 10.1038/leu.2013.240 Lee, 2017, IL-23R-activated STAT3/STAT4 is essential for Th1/Th17-mediated CNS autoimmunity, JCI Insight, 2, 91663, 10.1172/jci.insight.91663 Lisak, 2012, Secretory products of multiple sclerosis B cells are cytotoxic to oligodendrocytes in vitro, J. Neuroimmunol., 246, 85, 10.1016/j.jneuroim.2012.02.015 Lisak, 2017, B cells from patients with multiple sclerosis induce cell death via apoptosis in neurons in vitro, J. Neuroimmunol., 309, 88, 10.1016/j.jneuroim.2017.05.004 Lovett-Racke, 1998, Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients – a marker of activated/memory T cells, J. Clin. Invest., 101, 725, 10.1172/JCI1528 Lovett-Racke, 2011, Th1 versus Th17: are T cell cytokines relevant in multiple sclerosis?, Biochim. Biophys. Acta, 1812, 246, 10.1016/j.bbadis.2010.05.012 Lovett-Racke, 2019, B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients, J. Neuroimmunol., 332, 187, 10.1016/j.jneuroim.2019.04.017 Lykken, 2014, Acute and chronic B cell depletion disrupts CD4+ and CD8+ T cell homeostasis and expansion during acute viral infection in mice, J. Immunol., 193, 746, 10.4049/jimmunol.1302848 Montalban, 2017, Ocrelizumab versus placebo in primary progressive multiple sclerosis, New Engl. J. Med., 376, 209, 10.1056/NEJMoa1606468 Naismith, 2010, Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial, Neurology, 74, 1860, 10.1212/WNL.0b013e3181e24373 Nielsen, 2017, Characterization of naïve, memory and effector T cells in progressive multiple sclerosis, J. Neuroimmunol., 310, 17, 10.1016/j.jneuroim.2017.06.001 Palanichamy, 2014, Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients, J. Immunol., 193, 580, 10.4049/jimmunol.1400118 Poli, 2009, CD56bright natural killer (NK) cells: an important NK cell subset, Immunology, 126, 458, 10.1111/j.1365-2567.2008.03027.x Quigley, 2007, CXCR5+ CCR7- CD8 T cells are early effector memory cells that infiltrate tonsil B cell follicles, Eur. J. Immunol., 37, 3352, 10.1002/eji.200636746 Sabatino, 2019, Anti-CD20 therapy depletes activated myelin-specific CD8+ T cells in multiple sclerosis, Proc. Natl, Acad. Sci. USA, 116, 25800, 10.1073/pnas.1915309116 Sawas, 2017, A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab, Br. J. Haematol., 177, 243, 10.1111/bjh.14534 Schuh, 2016, Features of human CD3+CD20+ T cells, J. Immunol., 197, 1111, 10.4049/jimmunol.1600089 Shen, 2003, A specific role for B cells in the generation of CD8 T cell memory by recombinant listeria monocytogenes, J. Immunol., 170, 1443, 10.4049/jimmunol.170.3.1443 Venken, 2008, Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level, Immunology, 123, 79, 10.1111/j.1365-2567.2007.02690.x Viglietta, 2004, Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis, J. Exp. Med., 199, 971, 10.1084/jem.20031579 Von Essen, 2019, Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis, Brain, 142, 120, 10.1093/brain/awy301